Andreas Pahl

Company: Heidelberg Pharma

Job title: Chief Scientific Officer

Seminars:

Antibody Targeted Amanitin Conjugates (ATACs) Overcome Resistance Mechanisms to Establish New Treatment Options for Difficult to Treat Cancers 5:30 pm

Discover how ATACs represent a new class of ADCs using the payload Amanitin, introducing a novel mode of action (inhibition of RNA polymerase II) into oncology therapy Highlighting how the unique MoA facilitates killing of dormant tumor cells (CSCs, TICs) and offers new treatment options for difficult to treat cancers and high-risk patients Reviewing HDP-101,…Read more

day: Day One